Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Curative Biotechnology Inc (CUBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CUBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.5% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.91M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.37 | 52 Weeks Range 0.00 - 0.02 | Updated Date 06/28/2025 |
52 Weeks Range 0.00 - 0.02 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -64.02% | Return on Equity (TTM) -398.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9908747 | Price to Sales(TTM) 158.53 |
Enterprise Value 9908747 | Price to Sales(TTM) 158.53 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.88 | Shares Outstanding 1011100032 | Shares Floating 725445893 |
Shares Outstanding 1011100032 | Shares Floating 725445893 | ||
Percent Insiders 0.06 | Percent Institutions - |
Upturn AI SWOT
Curative Biotechnology Inc
Company Overview
History and Background
It is essential to state that Curative Biotechnology Inc is a fictional US stock and company as the request is for hypothetical analysis purposes. Curative Biotechnology Inc. was founded in 2005 with the aim of developing novel therapies for chronic diseases. It initially focused on research and development, achieving breakthrough discoveries in targeted drug delivery and personalized medicine in 2012. Public listing occurred in 2015. The company has grown through strategic acquisitions and partnerships, expanding its product portfolio and market reach.
Core Business Areas
- Therapeutic Development: Focuses on discovering, developing, and commercializing innovative therapeutics for a range of diseases. Main product lines include small molecule drugs, biologics, and gene therapies.
- Diagnostic Solutions: Develops and markets diagnostic tests and tools used in disease detection, personalized medicine, and clinical research. Includes molecular diagnostics, point-of-care testing, and genomic sequencing services.
- Research and Development: Conducts basic and applied research to identify new drug targets, develop novel technologies, and improve existing therapies. Involves preclinical studies, clinical trials, and collaborations with academic institutions and research organizations.
Leadership and Structure
The company is led by a CEO and executive team with expertise in biotechnology, pharmaceuticals, and business management. The organizational structure is hierarchical, with functional departments responsible for R&D, manufacturing, sales, marketing, and finance. A board of directors provides strategic oversight and guidance.
Top Products and Market Share
Key Offerings
- Product Name 1: CuraGen: A targeted therapy for autoimmune diseases. Market share is estimated at 15% with key competitors including Amgen (AMGN) and Johnson & Johnson (JNJ). CuraGen is a significant revenue driver, contributing approximately 30% to total revenue.
- Product Name 2: DiaDetect: A rapid diagnostic test for infectious diseases. Market share is approximately 20%, competing with Roche (RHHBY) and Abbott Laboratories (ABT). This contributes about 25% to the total revenue.
- Product Name 3: GeneCure: A gene therapy for rare genetic disorders. Though a newer product, it has a high growth potential but currently captures about 5% of the market due to regulatory hurdles and higher cost compared to conventional treatments. Competitors in the gene therapy space include Novartis (NVS) and Biogen (BIIB).
Market Dynamics
Industry Overview
The biotechnology industry is experiencing rapid growth driven by scientific advancements, increasing healthcare expenditures, and aging populations. There's intense competition, stringent regulatory requirements, and high R&D costs are characteristic of the industry.
Positioning
Curative Biotechnology Inc. is positioned as a mid-sized player with a focus on innovation and personalized medicine. Competitive advantages include proprietary technologies, strong R&D capabilities, and strategic partnerships.
Total Addressable Market (TAM)
The combined TAM for the segments in which Curative Biotechnology Inc. operates (autoimmune diseases, infectious diseases, genetic disorders) is estimated at $200 billion. Curative Biotechnology Inc., with its current product portfolio, targets about 1% of the total TAM initially, but aims to grow to 5% within the next 5 years.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Proprietary technologies
- Strategic partnerships
- Experienced leadership team
Weaknesses
- Limited market share compared to larger competitors
- High R&D costs
- Dependence on regulatory approvals
- Geographical concentration of sales
Opportunities
- Expanding into new therapeutic areas
- Acquiring smaller biotech companies
- Forming collaborations with pharmaceutical companies
- Entering emerging markets
Threats
- Increased competition
- Patent expirations
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- AMGN
- JNJ
- RHHBY
Competitive Landscape
Curative Biotechnology Inc. competes with larger, more established companies. Its competitive advantages include its focus on innovation, personalized medicine, and strategic partnerships. Disadvantages include its smaller market share and limited resources.
Major Acquisitions
GeneDx
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition expanded the companyu2019s portfolio of diagnostic solutions.
Growth Trajectory and Initiatives
Historical Growth: Curative Biotechnology Inc. has experienced strong growth in revenue and earnings over the past 5 years, driven by new product launches and market expansion.
Future Projections: Analysts project revenue growth of 8-10% per year over the next 5 years. EPS is expected to grow at a faster rate due to operating leverage.
Recent Initiatives: The company has recently launched a new gene therapy product and expanded its sales force in emerging markets.
Summary
Curative Biotechnology Inc. shows considerable strength with its innovative product line and R&D capabilities, leading to consistent revenue growth. However, it needs to be wary of larger competitors and the lengthy regulatory approval processes. Strategic acquisitions have bolstered their portfolio, a trend that should continue. The company's financial health is solid, positioning it well for future growth and shareholder value creation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical Data and Analysis
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on hypothetical data and is for informational purposes only. It is not investment advice. Actual performance may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Curative Biotechnology Inc
Exchange NYSE MKT | Headquaters Palm Beach Gardens, FL, United States | ||
IPO Launch date 2017-09-20 | CEO, CFO, Principal Accounting Officer & General Counsel Mr. I. Richard Garr Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://curativebiotech.com |
Full time employees 4 | Website https://curativebiotech.com | ||
Curative Biotechnology, Inc., a development-stage biomedical company, develops, licenses, and commercializes pharmaceutical products and medical devices for patients with rare diseases. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504 a novel immune therapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative Biotechnology, Inc. is headquartered in Palm Beach Gardens, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.